1625 – Dinutuximab beta for high-risk neuroblastoma

Page last updated: 23 October 2020

Application Detail

Description of Medical Service

Dinutuximab beta is indicated for the treatment of high-risk neuroblastoma in patients who have previously received induction chemotherapy and achieved at least a partial response. Dinutuximab beta is an antibody directed against the carbohydrate moiety of disialoganglioside 2 (GD2), which is overexpressed on neuroblastoma cells. After binding, dinutuximab beta induces cell death through complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity.

Description of Medical Condition

Neuroblastoma is an embryonal tumour of the autonomic nervous system and usually occurs in young children. The tumours are found in sympathetic nervous system tissues, typically in the adrenal medulla or paraspinal ganglia and can present as mass lesions in the neck, chest, abdomen, or pelvis.

Reason for Application

Health technology assessent

Medical Service Type


Previous Application Number/s

Not Applicable

Associated Documentation

Application Form


Consultation Survey

Consultation Survey (PDF 561 KB)
Consultation Survey (Word 70 KB)

PICO Confirmation


Assessment Report


Public Summary Document

Public Summary Document (PDF 741 KB)
Public Summary Document (Word 596 KB)

Meetings for this Application




12 June 2020


28-29 July 2020